Cancer Breakthrough at Rice University

Vibrating molecules destroyed 99% of cancer cells in lab tests using nothing more than light and a dye already used in medical imaging though human trials remain years away

A cancer treatment technique nicknamed the "molecular jackhammer" is drawing renewed attention after laboratory experiments showed specially designed molecules could destroy up to 99 percent of cultured melanoma cells when activated by near-infrared light. Researchers at Rice University, working in collaboration with colleagues at Texas A&M University and the University of Texas MD Anderson Cancer Center, describe the technique as a fundamentally new approach to killing cancer cells using mechanical force rather than drugs or radiation.

How It Works

The approach relies on amino cyanine molecules, synthetic dyes already widely used in medical imaging to mark and visualize cells. When these molecules are exposed to near-infrared light, they begin to vibrate in perfect synchrony at roughly 40 trillion oscillations per second, forming what physicists call a plasmon. That vibration generates enough mechanical force to physically tear open the membrane of a cancer cell, killing it through a process resembling a jackhammer breaking apart concrete.
"It is a whole new generation of molecular machines that we call molecular jackhammers," said Rice University chemist James Tour, whose lab has previously used related nanoscale compounds to drill through the membranes of infectious bacteria and treatment-resistant fungi. Ciceron Ayala-Orozco, a research scientist in Tour's lab and lead author of the original study, said the discovery marks the first time a molecular plasmon has been used to produce mechanical action aimed specifically at tearing apart a cancer cell's membrane.

Fast, Low-Dose, and Hard to Resist

Results from the original study, published in Nature Chemistry, showed the technique achieved 99 percent efficiency at destroying human melanoma cells in lab cultures, using very low concentrations of the molecules and comparatively low doses of light. In mouse models of melanoma, half of the treated animals became cancer-free. The mechanical action works within minutes, considerably faster than treatments like photodynamic therapy, according to Ayala-Orozco.
One of the technique's most notable advantages, researchers say, is that cancer cells are unlikely to develop resistance to a purely mechanical mode of attack, unlike the drug resistance that frequently undermines chemotherapy over time. Because near-infrared light can penetrate roughly 10 centimeters into human tissue, compared with just a few millimeters for visible light, researchers believe the approach could eventually reach deep-seated tumors, including those in the pancreas.
Follow-up research published in Advanced Science has since expanded the original molecule into more than 75 structural variations, opening the door to fine-tuning the technique for different cancer types. Researchers have also found that low, inactive doses of the molecules are safely internalized and cleared by normal cells, addressing early questions about potential toxicity.

Where the Research Stands Now

As of 2026, the Rice University-led team is reportedly expanding testing to additional cancer types, including triple-negative breast cancer, pancreatic tumors, and osteosarcoma, while working to optimize how the near-infrared light is delivered to tumors located deeper inside the body. According to researchers involved in the project, at least one company has expressed interest in licensing the technology, and investigators have said the aminocyanine molecules' similarity to existing FDA-approved imaging dyes could help streamline the path toward clinical approval.

A Long Road to Patients

Despite the encouraging early data, researchers and outside experts are careful to stress that the technique remains an experimental laboratory technology, not a treatment currently available to patients. All results published so far come from cell cultures and mouse models, and translating that same effectiveness into humans is far from guaranteed. Ayala-Orozco has previously estimated that, if development continues successfully, human clinical trials could begin within five to seven years.
Researchers have also cautioned against confusing the technique with unrelated wellness products, noting explicitly that the method has nothing to do with sound therapy, infrared lamps, frequency devices, or other unproven home remedies sometimes marketed using similar language.